$ICLR News
Last published 1d ago
- 1d agoICLRICON to Participate at Upcoming Investor ConferencesBusiness WireDUBLIN--(BUSINESS WIRE)--ICON to Participate at Upcoming Investor Conferences
- 2w agoICLRICON Reports Third Quarter 2026 ResultsBusiness WireThird Quarter 2026 Key Highlights Strong commercial performance with net business wins in the quarter of $3,150 million; a net book-to-bill of 1.56x and closing backlog of $24.5 billion, up 4.8%
- 1mo agoICLRICON Schedules Third Quarter 2026 Earnings Conference CallBusiness WireICON plc, (NASDAQ:ICLR) a world-leading clinical research organization, today announced that it will release its financial results for the third quarter 2026 after the market closes on Tuesday, October 27, 2026. The
- 2mo agoICLRICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and SustainabilityBusiness WireICON plc (NASDAQ:ICLR) ("ICON"), a world-leading clinical research organisation, today releases its ICON Cares 2025 Report which outlines how the company is delivering on its environmental, social and
- 3mo agoICLRICON Announces Pricing of USD 2.15 Billion NotesBusiness WireICON plc (NASDAQ:ICLR) ("ICON"), a world-leading clinical research organization, today announced the pricing by its wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the
- 3mo agoICLRICON Announces Private Offering of NotesBusiness WireICON plc (NASDAQ:ICLR) ("ICON"), a world-leading clinical research organization, announced today that its wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the "Issuer"),
- 3mo agoICLRICON Announces Results of Annual General MeetingBusiness WireICON plc (NASDAQ:ICLR), a world-leading clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 31, 2026 were duly passed by shareholders.
- 3mo agoICLRICON Reports Second Quarter 2026 ResultsBusiness WireHighlights Quarter two revenue of $2,063.5 million, an increase of 1.4% on quarter one 2026. Quarter two adjusted EBITDA of $327.2 million or 15.9% of revenue, an increase of 3.0% on quarter one 2026. GAAP net
- 3mo agoICLRICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trialsBusiness WireICON plc (NASDAQ:ICLR) today announced a multi-year collaboration with Anthropic to bring Claude’s AI capabilities across the clinical trial lifecycle. The collaboration further advances ICON’s digital innovation and
- 3mo agoICLRICON Schedules Second Quarter 2026 Earnings Conference CallBusiness WireICON plc, (NASDAQ:ICLR) a world-leading clinical research organization, today announced that it will release its financial results for the second quarter 2026 after the market closes on Wednesday, July 29, 2026. The
- 4mo agoICLRICON Reports First Quarter 2026 ResultsBusiness WireHighlights Quarter one revenue of $2,034.0 million, an increase of 0.9% on quarter one 2025. Quarter one adjusted EBITDA of $317.7 million or 15.6% of revenue. GAAP net income for the quarter of $104.8 million
- 4mo agoICLRICON selects Microsoft as a preferred technology partner to power AI-enabled clinical developmentBusiness WireICON plc (NASDAQ:ICLR) today announced that it has selected Microsoft as a preferred technology partner – further advancing ICON’s previously announced plan to invest in digital innovation and AI over the next three
- 4mo agoICLRICON Schedules First Quarter 2026 Earnings Conference CallBusiness WireICON plc, (NASDAQ:ICLR) a world-leading clinical research organization, today announced that it will release its financial results for the first quarter 2026 after the market closes on Tuesday, June 23, 2026. The
- 5mo agoICLRICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee InvestigationBusiness WireHighlights Quarter four revenue was $2,112.5 million. Full year revenue was $8,251 million. Quarter four adjusted EBITDA of $327.1 million or 15.5% of revenue; full year adjusted EBITDA of $1,530.7 million or
- 5mo agoICLRICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from NasdaqBusiness WireICON plc (NASDAQ:ICLR), a world-leading clinical research organization, today announced that it will release financial results for the fourth quarter and full year 2025 results after the market closes on Wednesday, May
- 6mo agoICLRICON expands US early phase research capabilities with new clinic and outpatient centresBusiness WireNew, 69.5K square-foot, state-of-the-art clinic in Texas integrates clinical, laboratory, and pharmacy infrastructure all under one roof Two new satellite outpatient clinics in Texas and Kansas will further expand
- 6mo agoICLRHealthVerity to Acquire Symphony Health, Uniting Clinical Data and Commercial Analytics to Accelerate Breakthroughs Across the Healthcare EcosystemGlobeNewswirePhiladelphia, PA, May 05, 2026 (GLOBE NEWSWIRE) -- HealthVerity, Inc., the leader in privacy-protected real-world data exchange and patient identity solutions, today announced that it has entered into a definitive
- 6mo agoICLRICON Provides Update on Audit Committee Investigation and Timing of Fourth Quarter and Full Year 2025 Financial ResultsBusiness WireICON plc (NASDAQ:ICLR), a world-leading clinical research organization, today announced that the Audit Committee of the Board of Directors has completed its investigation into certain of the Company's accounting
- 7mo agoICLRICON and Advarra Introduce New 'Research-Ready,' Connected Site Network ModelBusiness WirePartnership will integrate ICON's clinical trial technology with Advarra's purpose-built system for research sites, embedded across a broad, deeply established global network. Partnership will reduce administrative
- 8mo agoICLRLowey Dannenberg, P.C. is Investigating ICON PLC (NASDAQ: ICLR) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the FirmGlobeNewswireNEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ICON PLC ("ICON" or the "Company") (NASDAQ:ICLR) for
- 9mo agoICLRICLR Down 30%: ICON plc Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the FirmGlobeNewswireBOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating ICON plc (NASDAQ:ICLR) for potential securities law violations. Investors who have lost money in their ICON plc investment should contact
- 9mo agoICLRICON plc Provides Update on Timing of Fourth Quarter and Full Year 2025 Earnings Results and Investigation into Accounting PracticesBusiness WireInvestigation's preliminary indications are that 2023 and 2024 revenue may have been overstated by less than 2% for each fiscal year ICON plc, (NASDAQ:ICLR) today announced that it intends to release its fourth
- 11mo agoICLRICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitiveBusiness WireICON plc (NASDAQ:ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey,
- 11mo agoICLRICON Survey Reveals Increasing Clinical Trial Startup Delays, Underscoring Need for Human-Centred Site Activation SolutionsBusiness WireICON plc (NASDAQ:ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup. The findings
- 12mo agoICLRICON plc to Present at the Jefferies London Healthcare ConferenceBusiness WireICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation, today announced that Mr. Barry Balfe, CEO of ICON plc and Mr. Nigel Clerkin, CFO of ICON plc, will present at the Jefferies London Healthcare
- 1y agoICLRICON Reports Third Quarter 2025 ResultsBusiness WireHighlights Quarter three revenue was $2,042.8 million representing an increase of 1.3% on quarter two 2025. Net income for the quarter was $2.4 million or $0.03 per diluted share. Quarter three adjusted
- 1y agoICLRICON plc Schedules Third Quarter 2025 Earnings Conference CallBusiness WireICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, October 22, 2025. The
- 1y agoICLRICON Announces CEO TransitionBusiness WireICON plc (NASDAQ:ICLR), a world-leading clinical research organisation, today announced that Dr. Steve Cutler has informed the Board of his decision to retire as Chief Executive Officer and the Board has appointed Mr.
- 1y agoICLRICON plc to Participate at Upcoming Investor ConferencesBusiness WireICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Mr. Barry Balfe, COO of ICON plc, will present at the Baird 2025 Global Healthcare
- 1y agoICLRICON Announces Results of Annual General MeetingBusiness WireICON plc (NASDAQ:ICLR), a world-leading clinical research organisation powered by healthcare intelligence, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025
- 1y agoICLRICON Reports Second Quarter 2025 ResultsBusiness WireHighlights Gross business wins in the quarter of $2,966 million, representing an increase of 10.6% on quarter one 2025. Net business wins in the quarter of $2,057 million; a net book to bill in the quarter of
- 1y agoICLRICON's Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking ReportBusiness WireICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a
- 1y agoICLRICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in SustainabilityBusiness WireICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the company's leadership
- 1y agoICLRICON plc Schedules Second Quarter 2025 Earnings Conference CallBusiness WireICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the second quarter 2025 after the market closes
- 1y agoICLRICON plc to Present at the William Blair 45th Annual Growth Stock ConferenceBusiness WireICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the William Blair 45th Annual Growth
- 1y agoICLRICON releases its ICON Cares 2024 ReportBusiness WireICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today releases its ICON Cares 2024 Report. The report outlines how the company is delivering on its
- 1y agoICLRGlobal ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapiesBusiness WireICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe
- 1y agoICLRICON Reports First Quarter 2025 ResultsBusiness WireHighlights Net business wins in the quarter of $2,022 million; a net book to bill in the quarter of 1.01. Closing backlog of $24.7 billion, an increase of 0.3% on quarter four 2024 and 6.0% on quarter one
- 1y agoICLRTLXAnne Whitaker Appointed as Non-Executive DirectorGlobeNewswireMELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive
- 1y agoICLRICON plc Schedules First Quarter 2025 Earnings Conference CallBusiness WireICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the first quarter 2025 after the market closes on
- 1y agoLOWICLRBetterInvesting™ Magazine Update on Lowe's Cos. (NYSE: LOW) and ICON PLC (NASDAQ: ICLR)PR NewswireLowe's recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and...
- 1y agoICLRICON Public Limited Company Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 11, 2025 to Discuss Your Rights - ICLRPR NewswireThe Gross Law Firm issues the following notice to shareholders of ICON Public Limited Company (NASDAQ: ICLR). Shareholders who purchased shares of...
- 1y agoICLRPARIS:FRICON Becomes the First Large Clinical Research Organization to Fully Integrate Medidata Clinical Data Studio, Streamlining Data Management and ReviewBusiness WireAdoption allows ICON to take full advantage of the Medidata "Data Experience," leveraging AI to unify data sources, standardize outputs, and reduce reconciliation efforts Medidata, a Dassault Systèmes brand and leading
- 1y agoICLRInvestors in ICON Public Limited Company Should Contact The Gross Law Firm Before April 11, 2025 to Discuss Your Rights – ICLRGlobeNewswireNEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ICON Public Limited Company (NASDAQ:ICLR). Shareholders who purchased shares of ICLR during the class
- 1y agoICLRThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 11, 2025 in ICON Lawsuit - ICLRPR NewswireThe Gross Law Firm issues the following notice to shareholders of ICON Public Limited Company (NASDAQ: ICLR). Shareholders who purchased shares of...
- 1y agoICLRInvestors in ICON Public Limited Company Should Contact The Gross Law Firm Before April 11, 2025 to Discuss Your Rights – ICLRGlobeNewswireNEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ICON Public Limited Company (NASDAQ:ICLR). Shareholders who purchased shares of ICLR during the class
- 1y agoICLRThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 11, 2025 in ICON Public Limited Company Lawsuit - ICLRPR NewswireThe Gross Law Firm issues the following notice to shareholders of ICON Public Limited Company (NASDAQ: ICLR). Shareholders who purchased shares of...
- 1y agoICLRICON plc to Present at Upcoming Investor ConferencesBusiness WireICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Leerink Partners Global Healthcare
- 1y agoICLRMural Health and ICON Announce Partnership to Enhance Participant and Site Experience in Clinical TrialsPR NewswireMural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc (NASDAQ: ICLR), a global healthcare intelligence and ...
- 1y agoAKYACMBMCSCODOMO+9Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix BoardBusiness WireBelieves Incumbent Board's Approval and Ongoing Pursuit of Reckless and Dilutive Proposed Merger with Akoya Biosciences Demonstrates Urgent Need for Refreshment